Nikolay Delev

机构：Bristol-Myers Squibb (Sweden)

发表论文 40 篇 · 总被引 715 次 · h-index 11

代表论文

• Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II , Randomized, Double‐Blind , Placebo‐Controlled Trial (2022 · Arthritis & Rheumatology · 被引 262)
• Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis (2019 · Arthritis Research & Therapy · 被引 80)
• Biological impact of iberdomide in patients with active systemic lupus erythematosus (2022 · Annals of the Rheumatic Diseases · 被引 37)
• Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study (2022 · Lupus Science & Medicine · 被引 37)
• Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce (2023 · Nature Reviews Rheumatology · 被引 29)
• Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials (2020 · ACR Open Rheumatology · 被引 21)